National Academies Press: OpenBook

Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence (2007)

Chapter: Appendix A Agenda for Information-Gathering Meeting, Geneva, December 2005

« Previous: 4 Taking Action
Suggested Citation:"Appendix A Agenda for Information-Gathering Meeting, Geneva, December 2005." Institute of Medicine. 2007. Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence. Washington, DC: The National Academies Press. doi: 10.17226/11731.
×

Appendix A
Agenda for Information-Gathering Meeting, Geneva, December 2005

COMMITTEE ON THE PREVENTION OF HIV INFECTION AMONG INJECTING DRUG USERS IN HIGH-RISK COUNTRIES

December 19–20, 2005

Geneva, Switzerland

December 19, 2005

9:00–9:15 a.m.

Welcome, Introductions, and Opening Statement

 

Hugh Tilson, M.D., Dr.PH.

Committee Chair

9:15–9:45 a.m.

Charge to the Committee

 

Peter Piot, M.D., Ph.D.

Executive Director, UNAIDS

Under Secretary-General of the United Nations

9:45–10:15 a.m.

Overview of Addiction

 

Michael Farrell, MRCPsych

Reader in Addiction Psychiatry, National Addiction Centre,

Institute of Psychiatry, King’s College, London

Suggested Citation:"Appendix A Agenda for Information-Gathering Meeting, Geneva, December 2005." Institute of Medicine. 2007. Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence. Washington, DC: The National Academies Press. doi: 10.17226/11731.
×

10:15–11:00 a.m.

Epidemiology of HIV/AIDS Among IDUs in High-Risk Countries and the Global Response

 

Peter Ghys, M.D.

Acting Associate Director, Epidemic Monitoring and Prevention, Department of Policy, Evidence and Partnerships, UNAIDS

 

Catherine Anita Hankins, M.D., MSc, FRCPC

Associate Director of Policy, Evidence and Partnerships

Chief Scientific Adviser

UNAIDS

11:00–11:15 a.m.

Break

11:15–12:45 p.m.

Evidence Regarding HIV Prevention for IDUs

 

Overview:

Gerry V. Stimson Ph.D.

Emeritus Professor, Imperial College London, and

Executive Director, International Harm Reduction Association

 

Review of needle and syringe exchange programs:

Dr. Alex Wodak FRACP, FChAM

Director, Alcohol and Drug Service

St. Vincent’s Hospital, Darlinghurst, Australia

 

Review of needle and syringe exchange programs:

Kerstin Käll, M.D., Ph.D.

Clinic for Dependency Disorders

University Hospital, Linköping, Sweden

 

Review of drug treatment strategies:

Michael Farrell, MRCPsych

Reader in Addiction Psychiatry, National Addiction Centre,

Institute of Psychiatry, King’s College, London

12:45–1:45 p.m.

Lunch

Suggested Citation:"Appendix A Agenda for Information-Gathering Meeting, Geneva, December 2005." Institute of Medicine. 2007. Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence. Washington, DC: The National Academies Press. doi: 10.17226/11731.
×

1:45–3:15 p.m.

Country Perspectives Panel: Asian and Pacific Countries

 

Zhang Fujie, M.D.

Director, Division of Treatment and Care National Center for AIDS-STD Control and Prevention, Chinese Center for Disease of Control and Prevention

 

Adeeba Kamarulzaman, MBBS, FRACP

Head, Infectious Diseases Unit

Department of Medicine

University of Malaya Medical Centre, Malaysia

 

Chris Beyrer, M.D., M.P.H.

Associate Professor, Department of Epidemiology

Director, Johns Hopkins Fogarty AIDS

International Training and Research Program

Director, Johns Hopkins Center for Public Health & Human Rights

Johns Hopkins Bloomberg School of Public Health (discussing Thailand)

3:15–3:30 p.m.

Break

3:30–5:45 p.m.

Country Perspectives Panel: Former Soviet States, Central, and Eastern European Countries

 

Saulius Caplinskas, M.D., Ph.D.

Director, Lithuanian AIDS Centre

Assoc. Prof., Mykolas Romeris University

 

Monica Ciupagea M.D.

Program Officer

International Harm Reduction Development Program

Open Society Institute, Budapest

 

Oleg Tchestnov, M.D.

Deputy Director of the International Department

Ministry of Health, Russia

Suggested Citation:"Appendix A Agenda for Information-Gathering Meeting, Geneva, December 2005." Institute of Medicine. 2007. Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence. Washington, DC: The National Academies Press. doi: 10.17226/11731.
×

 

Ksenia Eroshina, M.P.H., Ph.D.

Head of Monitoring & Evaluation Department

Open Health Institute, Moscow, Russia

 

Alexey Mazus M.D.

Head of Moscow AIDS Center

 

Inga Upmace, M.D.

Deputy Director, AIDS Prevention Center, Latvia

Steering Committee member of CEE-HRN

(Central and Eastern Europe Harm Reduction Network)

 

Lily Hyde

Harm Reduction and IEC Consultant

International HIV/AIDS Alliance in Ukraine

6:30 p.m.

Reception for all meeting participants at the ILO building, hosted by UNAIDS

December 20, 2005

8:30–10:00 a.m.

Lessons Learned: Experiences in the United States, Canada, Australia, and Western European Countries

 

Don C. Des Jarlais, Ph.D.

Director of Research, Baron Edmond de Rothschild Chemical Institute, Beth Israel Medical Center

Professor of Epidemiology, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York

 

Alex Wodak, FRACP, FChAM

Director, Alcohol and Drug Service

St. Vincent’s Hospital, Darlinghurst, Australia

 

Roel A. Coutinho, M.D., Ph.D.

Director, Centre for Infectious Disease Control

National Institute for Health and the Environment, The Netherlands

Suggested Citation:"Appendix A Agenda for Information-Gathering Meeting, Geneva, December 2005." Institute of Medicine. 2007. Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence. Washington, DC: The National Academies Press. doi: 10.17226/11731.
×

 

Gerry V. Stimson Ph.D.

Emeritus Professor, Imperial College London, and

Executive Director, International Harm Reduction Association

10:00–10:15 a.m.

Break

10:15–12:30 p.m.

Illicit Drug Policies and the HIV Epidemic

 

Andrew Ball, M.B., B.S., FChAM

Senior Strategy and Operations Advisor

Department of HIV/AIDS

World Health Organization

 

Christian Kroll

Senior Coordinator, HIV/AIDS Unit

Global Coordinator on HIV/AIDS

UNODC

 

Chris Beyrer, M.D., M.P.H.

Associate Professor, Department of Epidemiology

Director, Johns Hopkins Fogarty AIDS International Training and Research Program Director, Johns Hopkins Center for Public Health & Human Rights

Johns Hopkins Bloomberg School of Public Health

 

Tomas Hallberg

Director, European Cities against Drugs (ECAD)

Stockholm, Sweden

 

George Zazulin

St. Petersburg Regional Director, ECAD, Russia

 

Alex Wodak, FRACP, FChAM

Director, Alcohol and Drug Service

St. Vincent’s Hospital, Darlinghurst, Australia

 

Raminta Stuikyte

Director, Central and Eastern European Harm Reduction Network

Suggested Citation:"Appendix A Agenda for Information-Gathering Meeting, Geneva, December 2005." Institute of Medicine. 2007. Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence. Washington, DC: The National Academies Press. doi: 10.17226/11731.
×

12:30–1:30 p.m.

Lunch

1:30–2:30 p.m.

Community Perspectives

 

Mr. Loon Gangte (not able to attend; sent written remarks)

President, Delhi Network of Positive People, India

Regional Coordinator for South Asia

Collaborative Fund for HIV Treatment Preparedness

 

Mr. Samuel Nugraha

Partnership and Network Assistant

UNAIDS Secretariat Indonesia

2:30–3:00 p.m.

Methodological Considerations in Evaluating Evidence

 

Don C. Des Jarlais, Ph.D.

Director of Research, Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center

Professor of Epidemiology, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, New York

3:00–3:30 p.m.

Public Comments

3:30 p.m.

Adjourn

Suggested Citation:"Appendix A Agenda for Information-Gathering Meeting, Geneva, December 2005." Institute of Medicine. 2007. Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence. Washington, DC: The National Academies Press. doi: 10.17226/11731.
×
Page 199
Suggested Citation:"Appendix A Agenda for Information-Gathering Meeting, Geneva, December 2005." Institute of Medicine. 2007. Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence. Washington, DC: The National Academies Press. doi: 10.17226/11731.
×
Page 200
Suggested Citation:"Appendix A Agenda for Information-Gathering Meeting, Geneva, December 2005." Institute of Medicine. 2007. Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence. Washington, DC: The National Academies Press. doi: 10.17226/11731.
×
Page 201
Suggested Citation:"Appendix A Agenda for Information-Gathering Meeting, Geneva, December 2005." Institute of Medicine. 2007. Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence. Washington, DC: The National Academies Press. doi: 10.17226/11731.
×
Page 202
Suggested Citation:"Appendix A Agenda for Information-Gathering Meeting, Geneva, December 2005." Institute of Medicine. 2007. Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence. Washington, DC: The National Academies Press. doi: 10.17226/11731.
×
Page 203
Suggested Citation:"Appendix A Agenda for Information-Gathering Meeting, Geneva, December 2005." Institute of Medicine. 2007. Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence. Washington, DC: The National Academies Press. doi: 10.17226/11731.
×
Page 204
Next: Appendix B Literature Search Strategies »
Preventing HIV Infection Among Injecting Drug Users in High-Risk Countries: An Assessment of the Evidence Get This Book
×
Buy Paperback | $83.00 Buy Ebook | $64.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Drug dependence is a complex, chronic, relapsing condition that is often accompanied by severe health, psychological, economic, legal, and social consequences. Injecting drug users are particularly vulnerable to HIV and other bloodborne infections (such as hepatitis C) as a result of sharing contaminated injecting equipment. All drug-dependent individuals, including injecting drug users (IDUs), may be at increased risk of HIV infection because of high-risk sexual behaviors. There are an estimated 13.2 million injecting drug users (IDUs) world-wide—78 percent of whom live in developing or transitional countries. The sharing of contaminated injecting equipment has become a major driving force of the global AIDS epidemic and is the primary mode of HIV transmission in many countries. In some cases, epidemics initially fueled by the sharing of contaminated injecting equipment are spreading through sexual transmission from IDUs to non-injecting populations, and through perinatal transmission to newborns. Reversing the rise of HIV infections among IDUs has thus become an urgent global public health challenge—one that remains largely unmet.

In response to this challenge, the Institute of Medicine convened a public workshop in Geneva in December 2005 to gather information from experts on IDU-driven HIV epidemics in the most affected regions of the world with an emphasis on countries throughout Eastern Europe, the Commonwealth of Independent States, and significant parts of Asia. Experts from other regions also provided information on their experiences in preventing HIV infection among IDUs. This report provides a summary of the workshop discussions.

Preventing HIV Infection among Injecting Drug Users in High Risk Countries describes the evidence on the intermediate outcomes of drug-related risk and sex-related risk prior to examining the impact on HIV transmission. This report focuses on programs that are designed to prevent the transmission of HIV among injecting drug users. These programs range from efforts to curtail non-medical drug use to those that encourage reduction in high-risk behavior among drug users. Although the report focuses on HIV prevention for IDUs in high-risk countries, the Committee considered evidence from countries around the world. The findings and recommendations of this report are also applicable to countries where injecting drug use is not the primary driver, but in which injection drug use is nevertheless associated with significant HIV transmission.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!